Your browser doesn't support javascript.
loading
The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation.
Tward, Jonathan; Lenz, Lauren; Flake, Darl D; Rajamani, Saradha; Yonover, Paul; Olsson, Carl; Kapoor, Deepak A; Mantz, Constantine; Liauw, Stanley L; Antic, Tatjana; Fabrizio, Michael; Salzstein, Daniel; Shore, Neal; Albertson, Dan; Henderson, Jonathan; Lee, Steve P; Gay, Hiram A; Michalski, Jeff; Hung, Arthur; Raben, David; Garraway, Isla; Lewis, Michael S; Nguyen, Paul L; Marshall, David T; Brawer, Michael K; Stone, Steven; Cohen, Todd.
Affiliation
  • Tward J; Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. Electronic address: jonathan.tward@hci.utah.edu.
  • Lenz L; Myriad Genetics, Inc, Salt Lake City, Utah.
  • Flake DD; Myriad Genetics, Inc, Salt Lake City, Utah.
  • Rajamani S; Myriad Genetics, Inc, Salt Lake City, Utah.
  • Yonover P; UroPartners, Chicago, Illinois.
  • Olsson C; Advanced Radiation Center of New York, New Hyde Park, New York, and Integrated Medical Professionals, North Hills, New York.
  • Kapoor DA; Advanced Radiation Center of New York, New Hyde Park, New York, and Integrated Medical Professionals, North Hills, New York.
  • Mantz C; 21st Century Oncology, Fort Meyers, Florida.
  • Liauw SL; Department of Radiation Oncology, University of Chicago Medical Center, Chicago, Illinois.
  • Antic T; Department of Pathology, University of Chicago Medical Center, Chicago, Illinois.
  • Fabrizio M; Urology of San Antonio, San Antonio, TX.
  • Salzstein D; Urology of Virginia, Norfolk, Virginia.
  • Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina.
  • Albertson D; Department of Anatomic Pathology and Molecular Oncology, University of Utah, Salt Lake City, Utah.
  • Henderson J; Regional Urology, LLC, Shreveport, Louisiana.
  • Lee SP; Department of Radiation Oncology, Long Beach VA Medical Center, Long Beach, California.
  • Gay HA; Department of Radiation Oncology, Washington University, St. Louis, Missouri.
  • Michalski J; Department of Radiation Oncology, Washington University, St. Louis, Missouri.
  • Hung A; Department of Radiation Medicine, Oregon Health & Science University, Portland, Oregon.
  • Raben D; University of Colorado, Aurora, Colorado.
  • Garraway I; Department of Urology, Greater Los Angeles-VA Medical Center, Los Angeles, California.
  • Lewis MS; Department of Urology, Greater Los Angeles-VA Medical Center, Los Angeles, California.
  • Nguyen PL; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Marshall DT; Department of Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina.
  • Brawer MK; Myriad Genetics, Inc, Salt Lake City, Utah.
  • Stone S; Myriad Genetics, Inc, Salt Lake City, Utah.
  • Cohen T; Myriad Genetics, Inc, Salt Lake City, Utah.
Int J Radiat Oncol Biol Phys ; 113(1): 66-76, 2022 05 01.
Article in En | MEDLINE | ID: mdl-34610388
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Androgen Antagonists Type of study: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2022 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Androgen Antagonists Type of study: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2022 Type: Article